Shin Nippon Biomedical Laboratories, Ltd.

Wave Life Sciences Japan, Inc.

The Chemo-sero-therapeutic Research Institute

Km Biologics Co., Ltd.

Ryoichi Nagata

Shunji Haruta

Takefumi Gemba

Tatsuo Tsutsui

Yutaka Kawakami

Ikumi Shiga

Masatoshi Kashima

Yusuke Torikai

Hiroaki Magotani

[Problem] To provide a urine scattering prevention device which does not give off a foul smell even when used, and which is easy to replace. [Solution] A urine scattering prevention deviceincludes a urine receiving portiondisposed in a urinaland a leg portionwhich supports the urine receiving portionvertically upward.

Urine scattering prevention device

To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. This micro-encapsulated aquaculture feed includes: an oil phasehaving an oil-soluble nutrient component; a water phasewhich is present inside the oil phase, and which includes a water-soluble nutrient component; and a filmwhich includes the oil phaseand the water phase. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.

Micro-encapsulated aquaculture feed

Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.

Methods and compositions for intranasal delivery

Problem To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. Solution An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5'-XCpGX-3&#x2032; and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3&#x2032; end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3&#x2032; end and 5&#x2032; end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.

Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent

[Subject] A test substance application system for animal experiment capable of administering a required amount of a test substance uniformly and reliably from a nose or a mouth into a nasal cavity or into a lung of an experimental animal is provided. [Means for Solution] The system includes a respiration monitoring devicethat monitors a respiration state of an experimental animal detected by a respiration pick-up deviceto thereby measure a timing upon switching from an expiratory phase to an inhalatory phase and outputs a trigger signal T at that timing, and an application devicethat sprays a predetermined amount of a test substance into a nasal cavity or an oral cavity of the experimental animal when the trigger signal T is outputted from the device

Test substance administration system for animal experiment

Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.

Preparation for transnasal application

Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5'-XCpGX-3&#x2032; and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3&#x2032; end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3&#x2032; end and 5&#x2032; end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.

Chiral nucleic acid adjuvant having antitumor effect and antitumor agent

Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5'-XCpG X-3&#x2032; and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3&#x2032; end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3&#x2032; end and 5&#x2032; end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.

Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator

When a primate is t restrained by a movable partition wall, friction with vertical bars of a lattice of the partition wall causing damages on roots of limbs of the primate is alleviated to reduce or solve such damages. In a primate restraint device comprising a containing body having both side surfaces, a top surface and a bottom surface, a rear surface door capable of opening and shutting the rear surface side of the containing body, and a partition wall formed movably frontward and rearward in the containing body and capable of being fixed at a desired position in the containing body, some sites among vertical bar members of the partition wall, with which roots of limbs of the primate are brought into contact while the limbs are forced to protrude frontward and restrained, are covered with protective cylinders which are rotatable with respect to the vertical bar members.

Primate restraint device

A primate restraint device capable of restricting the movement of a monkey and, particularly, capable of facilitating injection or blood collection. A primate restraint device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. The partition wall has provided therein hind-limb protrusion openings from which the hind limbs of the contained primate are caused to protrude to the outside.

Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed.

Intranasal pharmaceutical compositions with improved pharmacokinetics

A primate restraint device capable of restricting the movement of a monkey and, particularly, capable of facilitating transnasal intragastric administration or oral administration. A primate restraint device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. Both side surfaces are each formed by combining vertical bar members and horizontal bar members into a grid pattern, and at least some of the horizontal bar members of the side surface are curved downward to form chin support sections on which the chin of the contained primate is supported.

Formulations and methods of manufacture are provided for granisetron dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations. Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices.

Intranasal granisetron and nasal applicator

Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.

Growing community of inventors

Kagoshima, Japan

Ryoichi Nagata